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Abstract
Background: Norovirus is the commonest cause of infectious intestinal disease (IID) worldwide. In the UK community
incidence of norovirus has been estimated at 59/1000 population, equating to four million cases a year. Whilst norovirus
infects people of all ages, a substantial burden occurs in infants and young children. The population of viruses found in
sporadic cases among infants has been observed to be more diverse than that associated with outbreaks. In this study,
we analysed norovirus-positive specimens collected during the second study of infectious intestinal diseases (IID2 Study)
a national community cohort study conducted between April 2008 and August 2009 We examined the data for
differences in circulating norovirus strains between two arms of a community cohort, and differences between
genotypes and disease outcomes such as illness duration and symptom profiles.
Methods: Analysis was conducted to assess genetic diversity of noroviruses in the community. We also assessed
differences in the cycle threshold (Ct) value, as a proxy for viral load, between norovirus genogroups and genotypes,
and differences in reported symptoms or length of illness in relation to genogroup and genotype.
Results: There were 477 samples where norovirus was detected. Whilst 85% of people recovered within two days for
vomiting; diarrhoea symptoms were reported to day 4 for 83% of the cases, and 10% of people reported symptoms of
diarrhoea lasting between five and six days. Both diarrhoea and vomiting symptoms lasted longer in children aged < 5
years compared to adults. There was a significantly higher proportion of GII.4 in samples obtained from the GP arm of
the study (chi-square = 17.8, p < 0.001) compared to samples received via post in the self-reporting arm. In the latter
group, the prevalence of GII.6 was significantly higher (chi-square = 7.5, p < 0.001).
Conclusions: We found that there is a difference in disease severity by age group. Children aged < 5 years had longer
duration of illness, with 10% still having diarrhoea at seven days, and vomiting of between four and five days. The
duration of illness reported is higher overall than one might expect for cases in the community in otherwise healthy
individuals which has implications for infection control. No differences were observed in relation to duration of
vomiting and or diarrhoea by genotype.
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Introduction
Norovirus is the commonest cause of infectious intes-
tinal disease (IID) worldwide [1]. Viruses of the genus
Norovirus (family Caliciviridae) have positive sense,
single-stranded RNA genomes that exhibit high rates of
mutation due to the error-prone nature of genome repli-
cation mediated by the low-fidelity viral RNA-dependent
RNA polymerase. In turn, this generates a substantial
amount of genetic diversity among the Norovirus genus:
human norovirus strains predominantly belong to gen-
ogroup I (GI) and genogroup II (GII) which are subdi-
vided into nine (GI.1-GI.9) and 22 (GII.1-GII.22)
genotypes, respectively [2, 3]. Despite this high degree of
diversity, norovirus strains of the GII.4 genotype are the
most frequently detected worldwide [4–7]. The mecha-
nisms by which GII.4 viruses persist and dominate in
the population are not fully understood, but it is at least
in part linked to the ability of these strains to rapidly
mutate generating new antigenic profiles that are able to
escape from population immunity [8–10].
In the UK, the Second Study of Infectious Intestinal
Disease (IID2 Study), described in detail elsewhere [11, 12]
utilised a prospective cohort design randomly selecting
healthy people of all ages from randomly selected general
practices (GP) across the UK with follow-up of volunteers
at weekly intervals for one year to detect symptoms and de-
termine the aetiology of cases of IID in the cohort, add-
itionally cases who attended GP surgeries from volunteer
practices also provided faecal specimens for analysis. A re-
cent reanalysis of the IID2 Study data estimated the com-
munity incidence of norovirus to be 59/1000 population,
equating to almost four million cases a year [13] .
From community-based studies such as the IID2
Study, and others [11, 14], it is increasingly clear that
whilst norovirus infects people of all ages across the
world, a substantial burden of norovirus-associated dis-
ease occurs in infants and young children [13, 15, 16]. It
has been observed that the population of viruses found
in sporadic cases among infants was more diverse than
that associated with outbreaks [17]. These data indicate
a need for better understanding of the molecular epi-
demiology of norovirus strains associated with sporadic
cases (as well as outbreaks), and circulating among chil-
dren and in the wider community.
Previous studies have shown an association between
norovirus infection and poorer outcomes in hospitalised
cases [18] and with increased age [19]. In this study, we
analysed norovirus-positive specimens collected during
the IID2 Study from either the GP presentation arm of
the study or the Prospective Cohort arm to determine
the diversity of norovirus genotypes associated with
cases of norovirus-associated IID in the community.
Further, we examined the data for differences in circulat-
ing norovirus strains between the two arms of the
community cohort, and differences between genotypes
and disease outcomes such as illness duration or symp-
tom profiles (vomiting/diarrhoea etc).
Methods
Setting
Cases were drawn from the community, i.e. did not
attend hospital, from two concurrent studies within the
IID2 study, firstly, where participants visited their GP for
symptoms related to infectious intestinal disease and
secondly, those who were part of a volunteer cohort,
recruited via GP surgeries and followed up at weekly in-
tervals, who self-reported illness [12]. The latter cases
were also asked about their contact with health services.
For this study the second group are categorised as other
community cases to distinguish them from those cases
ascertained from the GP presentation arm of the IID2
study [12].
Case definition
Cases were defined as people developing clinically sig-
nificant vomiting (more than once in a 24 h period, or
where it caused incapacity or was accompanied by other
symptoms) or loose stools for a period of less than two
weeks, without a known non-infectious cause and who
had previously been symptom free in the preceding
three weeks. Cases were asked to complete a clinical
symptom questionnaire. If vomiting was associated with
non-infectious causes such as pyloric stenosis or morn-
ing sickness, these were excluded from the case
definition.
Laboratory methods
Cases were asked to provide stool samples for microbio-
logical examination. Diagnosis of norovirus was by real
time quantitative reverse transcription polymerase chain
reaction (RT-PCR) [12] . In the original study (IID2),
clinically relevant cases of norovirus were defined as
those where detection occurred with a cycle threshold
(Ct) of < 30. This study attempted to genotype all of the
stool samples in which norovirus was detected with a Ct
value of < 40 as this value is more in line with that nor-
mally used in clinical diagnostic laboratories [13] . Geno-
typing was performed by amplification of the S domain
encoding region of the VP1 gene (ORF2, region C) [20],
followed by direct Sanger sequencing, and genotypes
were assigned as described elsewhere [21].
Statistical analysis
Initial analysis was conducted to assess which genotypes
occurred in the community and if these differed between
those attending their GP and those who self-report ill-
ness. We also assessed differences in Ct values as a
proxy for viral load, between the genogroups and
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genotypes. Analysis was conducted where there were at
least five samples with a measureable Ct value in each
genotype. Data were also investigated to assess differ-
ences in self-reported symptoms, gathered by standard
questionnaire, or length of illness in relation to gen-
ogroup and genotype (chi square test). Analysis was con-
ducted using the R statistical package [22].
Results
There was a total of 477 samples where norovirus was de-
tected. The distribution of samples by age at submission
in cases is shown in Table 1. The greatest number of sam-
ples were in the youngest age group (0–4 years) and in
adults aged 25–64 years. The fewest number of samples
were from young adults aged 16–24 years (Table 1).
There were slightly more female participants overall
with 52.83% females and 46.33% males. However, there
were significant differences in the proportion of males
and females by age group (chi square = 45, p < 0.001),
with twice as many males compared to females in the
youngest age group (0–4 years), In the 16–64 years age
group there was a greater proportion of females (74%)
than males. The older age group (> = 65 years) males
and females were equally represented (Fig. 1).
Table 2 shows the distribution of genotypes by age and
surveillance arm. The majority of samples were GII
(91.4%). There were 40 (8.39%) GI and one sample was
mixed GI and GII. Ninety four percent (448) (93.9%)
were assigned to a single genotype, and 28 samples
could not be typed (6.1%). In those samples identified as
GII, the majority were GII.4 (52.29%) whereas for GI
samples GI.3 and GI.4 were the predominant types (32.5
and 22.5% respectively).
There was a significantly higher proportion of GII.4 in
samples obtained from the GP arm of the study (chi-s-
quare = 17.8, p < 0.001) compared to samples received
via post in the self-reporting arm. In the latter group,
the prevalence of GII.6 was significantly higher (chi-s-
quare = 7.5, p < 0.001).
There was no statistically significant difference in the
Ct values between the genotypes, however the median
Ct value for those samples from which a genotype could
not be determined was higher than those samples that
were genotyped. The Ct values for specimens where the
virus could not be genotyped clustered towards higher
values (Inter Quartile Range (IQR) 21.42–37.9), and the
median value 32.95 was above the cut off value of 30
[23] used in the IID2 study as a measure of symptomatic
infection (Figs. 2 and 3).
Analysis of symptoms showed that vomiting and
diarrhoea were the commonest symptoms reported
(Table 3). Other commonly reported symptoms were
nausea, loss of appetite and abdominal pain. There was
no difference in the proportion of reported symptoms by
virus genogroup or genotype (Chi square = 11.75, p =
0.761, note chi square test excludes the mixed category).
Diarrhoea symptoms lasted for an average of 2.8 days
(median 2, IQR 1–4) and vomiting symptoms lasted for
an average of 1.7 (median 1 IQR 1–2).
Whilst 85% of people reported recovery within two
days for vomiting, diarrhoea symptoms were reported to
day 4 for 83% of the cases. Ten percent of people had
symptoms of vomiting lasting 2 to 3 days, whereas 10%
of people reported symptoms of diarrhoea lasting be-
tween five and six days. The median reported length of
absence from work or school was 2 days with 87% of
people reporting having three or fewer days absence
(Fig. 4). Both diarrhoea and vomiting symptoms lasted
longer in children under 5 than in adults.
Discussion
In this study we have shown that community sporadic
cases of norovirus infections are dominated by gen-
ogroup II noroviruses (88%), this is in line with other
studies [4, 5, 24] and also with the data from national
surveillance in England [25]. National surveillance pri-
marily represents norovirus outbreaks, and predomin-
antly from disease associated with health care settings.
Data from national surveillance during the same period
in which the IID-2 sample collection (data not shown)
took place showed that GII strains represented 91% of
the total of strains received. In this study 6% of the
strains were GI (compared to 9% in the national surveil-
lance) and among both data sets GI-3 was the predom-
inant genotype (46% in the IID study and 44% for
national surveillance). Genogroup II viruses were domi-
nated by genotype II.4 (54% in the IID cohort and 84%
in national surveillance) There was a significant differ-
ence in the proportion of genogroup II.4 found in those
where samples were taken from patients attending their
GP compared to other community sources.
In this study formal assessment of disease severity was
not carried out, and although no differences were ob-
served in relation to duration of vomiting and or diar-
rhoea by genotype, we found that there is a difference in
Table 1 Age distribution of participant’s samples
age group Number of samples Percent of total samples
0–4 121 25.37
5–15 50 10.48
16–24 10 2.10
25–49 100 20.96
50–64 116 24.32
65+ 76 15.93
Not known 4 0.84
Total 477 100
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disease severity by age group. Whilst, most people had
recovered from their symptoms within three days, a pro-
portion of cases reported symptoms lasting longer than
this. For example, 10% of patients reported diarrhoea
symptoms at between five and six days duration. Chil-
dren aged < 5 years had longer duration of illness, with
10% still having diarrhoea at seven days, and vomiting of
between four and five days. In older children and adults
these figures were four and two days respectively. The
proportion of people reporting diarrhoea symptoms last-
ing four days or more is a concern for control of infec-
tious diseases especially for adults involved in
preparation of food or those who are involved in health
care roles. Nevertheless, the duration of illness reported
Fig. 1 Norovirus cases by age group and sex
Table 2 Distribution of genotypes by age group and surveillance arm
Genotype
Surveillance arm/
age group
GI.2 GI.3 GI.4 GI.5 GI.6 GI
Untyped
GII.1 GII.13 GII.2 GII.3 GII.4 GII.6 GII.7 GII.8 GII.9 GII
Untyped
Mixed
genotypea
Total
GP arm
0–4 – – – – – 1 2 – – 13 27 5 1 – – 3 – 52
05–15 – 1 1 – – – – – – – 2 4 1 – – – – 9
16–49 – 2 - – 1 – 1 – 2 2 21 4 2 1 – 2 – 38
50–64 – 1 1 – 1 1 3 – – 2 26 – – – – – – 35
65+ – - 1 – – – – – – 1 24 1 – 1 – – – 28
Not known – - - – – 2 – – – – – – – – – – – 2
Sub total – 4 3 – 2 4 6 – 2 18 100 14 4 2 – 5 – 164
Self-reporting arm
0–4 – – 2 – – 1 3 – 7 7 26 14 5 – – 3 1 69
05–15 1 2 – 1 – 1 6 – 7 1 8 10 2 1 – 1 – 41
16–49 – 3 – – 1 2 4 1 5 7 31 13 1 – – 4 – 72
50–64 1 2 1 – – 2 8 – 3 9 38 9 4 1 1 2 – 81
65+ – 2 2 – – 2 4 – 2 1 24 10 – – – 1 – 48
Not known – – 1 – – – – – – – 1 – – – – – – 2
Sub total 2 9 6 1 1 8 25 1 24 25 128 56 12 2 1 11 1 313
Total 2 13 9 1 3 12 31 1 26 43 228 70 16 4 1 16 1 477
aNote: the mixed genotype sample was: GI-3 / GII-6
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is higher than one might expect for cases in the commu-
nity given that these people are generally healthy. Hospi-
talised patients are known to have a longer duration of
illness compared to health care workers and care home
patients and this is likely related to their underlying
health [18]. Our findings and also the fact that most
hospital or healthcare associated outbreaks of norovirus
(from national surveillance) tend to be predominantly
associated with GII.4 norovirus, suggest that GII.4 might
be associated with more severe disease requiring medical
attention. This might also reflect issues around under-
standing when diarrhoea stops and simply how long the
bowel takes to settle down after infection. It is easy to
state when vomiting has ceased, perhaps less clear when
diarrhoea ends.
There was no statistical difference in the Ct values by
genotype. Genotypes GI.3 and GII.3 had the lowest me-
dian Ct values 22.4 and 22.5 respectively. Samples that
were un-typed had the highest median Ct value at 33.
There were only 26 samples in this group, and 50 % of
these were between 33 and 39.4, and only four samples
had Ct values below 20. The high median value of this
group suggests the samples had a low viral load and this
might explain why they were not able to be genotyped.
Young children (aged < 5 years) also had lower median
Ct values than other age groups but there was no rela-
tionship between age and genotype. Young children
(aged < 5 years) were the largest single age group in the
analysis followed by older adults (aged 50–64 years).
This is not surprising given that norovirus rates are
Fig. 2 Distribution of ct values by genotype
Fig. 3 Distribution of ct values by genogroup
Harris et al. BMC Infectious Diseases           (2019) 19:87 Page 5 of 8
higher in those aged < 5 years [13]. One reason for
higher rates of infection in children could be associated
with severity of symptoms, for example; if symptoms
persist for more than two or three days, parents might
be more likely to contact medical services. An interest-
ing point is that the proportion of males in the youngest
age groups was greater than females, in the age group
0–4 years the ratio of males to females was 2:1 and in
the 5–15 years age group the ratio was 1.6:1. In older
age groups this ratio changed and females were more
greatly represented than males. In the 16 to 49 age
group the ratio was almost 3:1 in favour of females. The
oldest age group saw equal proportions of males and
females. The drivers of these differences in ratios for
males to females in the different age groups is difficult
to explain from this data. Animal model data suggests
sex differences for infections in animals implicating the
role of male sex hormones in increasing susceptibility to
infection in males. There are differences in the develop-
ing immune systems of the sexes in humans related to
differences in sex hormones which can affect immunity
in infants and the very young and therefore, differential
observations of infectious diseases between the sexes
[26]. It should be noted that data from Public Health
England (PHE) on norovirus laboratory reports suggests
that the male/female ratio is nearer parity in young chil-
dren aged < 10, and slightly increased numbers of
females in age groups of young adults to age 59 and a
Table 3 Symptoms by genogroup/genotype
Genogroup Diarrhoea Vomiting Diarrhoea & vomiting Abdominal Pain Nausea Loss of appetite Fever Headache Sinusa Total
GI 11 5 18 19 26 29 18 15 12 40
GII4 55 22 128 128 146 178 65 83 57 228
GIInot4 38 30 98 91 110 137 60 61 58 208
mixed 0 0 1 0 0 1 1 1 1 1
aCough/runny or blocked nose or sore throat
A
B
C
Fig. 4 Length of time for recovery from symptoms of norovirus a All ages b aged < 5 years c ages > = 5 years
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much greater proportion of females in those aged 80
and over. Therefore one of the main limitations of the
study is the lack of participation of young adults, par-
ticularly those aged 16–24 years and the differences in
the sexes in the different age groups. This might be
linked to characteristics of health seeking behaviour. It is
also well documented that people with serious under-
lying health conditions shed norovirus in their stools for
a long time [27, 28] and for the elderly or those with ser-
ious underlying conditions there is a measurable attribu-
tion to mortality [19]. This finding is likely a reflection
on the proportion of very young.
A further limitation is that the typing of norovirus was
conducted using only region C and as such although we
describe capsid types, we are not able to report on poly-
merase types and recombinant strains circulating among
the population surveyed. However, analysis of capsid
types in this study aligns with methods used in national
surveillance typing of norovirus in England and Wales,
and so allows us to compare viruses circulating in the
community with those associated with outbreaks, which
are the majority of those collected through national sur-
veillance. In future studies, this limitation is likely to be
ameliorated as whole genome sequencing techniques for
analysis of norovirus become more accessible, which will
yield data on capsid, polymerase and recombinant
genomes.
Despite the limitations, this study shows the preva-
lence of GII.4 noroviruses in the community from two
community settings, GP and non-GP settings. Samples
were taken within three days in non GP settings and
within nine days of GP consultation. Furthermore illness
can last for several days, longer than expected in other-
wise healthy individuals which has implications for in-
fection control.
Abbreviations
Ct: Cycle threshold; GP: General practice/practitioner; HPRU: Health
Protection Research Unit; IID: Infectious Intestinal Disease; NIHR: National
Institute for Health Research; RT-PCR: Reverse transcription Polymerase Chain
Reaction
Acknowledgements
See funding.
Funding
The research was funded by the National Institute for Health Research Health
Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at
University of Liverpool in partnership with Public Health England (PHE), in
collaboration with University of East Anglia, University of Oxford and the
Quadram Institute [Grant number NIHR HPRU 2012–10038]. The views
expressed are those of the author(s) and not necessarily those of the NHS,
the NIHR, the Department of Health or Public Health England.
The IID2 Study was originally funded by the United Kingdom Food
Standards Agency and the Department of Health [Grant number FS231043
(B18021)]. We also thank the Wellcome Trust for funding for this work (Grant
Reference 203268/Z/16/Z).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
JPH, MIG, designed the study and analysis, SK contributed to the analysis
and early draft, SJOB, DJA also contributed to the text and analysis. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
A favourable ethical opinion to perform the whole of the study was granted
by the North West Research Ethics Committee (07/MRE08/5). Research
management and governance was then sought, and approval granted by all
relevant Research and Development Organisations across the United
Kingdom [ref: O’Brien et al. BMC Medical Research Methodology 2010, 10:39].
The IID2 study obtained and recorded oral informed consent from
participants in the Telephone Survey using the CopyCall Telephone
Recorder. We obtained written informed consent from all adults in the
prospective studies. We obtained written informed assent from children and
written informed consent from their parent or guardian. [ref: The second
study of Infectious Intestinal Disease in the Community (IID2 Study) https://
www.food.gov.uk/sites/default/files/media/document/711-1-
1393_IID2_FINAL_REPORT.pdf].
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Liverpool, Instutue of Population Health Sciences, Liverpool,
UK. 2University of Liverpool Institute of Global Health, Liverpool, UK. 3London
School of Hygiene and Tropical Medicine, Liverpool, UK. 4NIHR HPRU in
Gastrointestinal Infections, Liverpool, UK. 5Modelling, Evidence and Policy
Research Group, School of Natural and Environmental Sciences, Newcastle
University, Newcastle upon Tyne, UK.
Received: 13 September 2018 Accepted: 10 January 2019
References
1. Belliot G, et al. The burden of norovirus gastroenteritis: an important
foodborne and healthcare-related infection. Clin Microbiol Infect. 2014;20(8):
724–30.
2. Kroneman A, et al. Proposal for a unified norovirus nomenclature and
genotyping. Arch Virol. 2013;158(10):2059–68.
3. Vinje J. Advances in laboratory methods for detection and typing of
norovirus. J Clin Microbiol. 2015;53(2):373–81.
4. Zakikhany K, et al. Molecular evolution of GII-4 norovirus strains. PLoS One.
2012;7(7):e41625.
5. Vega E, et al. Genotypic and epidemiologic trends of norovirus outbreaks in
the United States, 2009 to 2013. J Clin Microbiol. 2014;52(1):147–55.
6. Mans, J., et al., Norovirus diversity in children with gastroenteritis in South
Africa from 2009 to 2013: GII.4 variants and recombinant strains
predominate. Epidemiol Infect, 2015: p. 1–10.
7. van Beek J, et al. Comparison of norovirus genogroup I, II and IV
seroprevalence among children in the Netherlands, 1963, 1983 and 2006. J
Gen Virol. 2016;97(9):2255–64.
8. Siebenga JJ, et al. Epochal evolution of GGII.4 norovirus capsid proteins
from 1995 to 2006. J. Virol. 2007;81(18):9932–41.
9. Lindesmith LC, et al. Mechanisms of GII.4 norovirus persistence in human
populations. PLoS Med. 2008;5(2):e31.
10. Allen DJ, et al. Analysis of amino acid variation in the P2 domain of the GII-
4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One.
2008;3(1):e1485.
Harris et al. BMC Infectious Diseases           (2019) 19:87 Page 7 of 8
11. Tam CC, et al. Longitudinal study of infectious intestinal disease in the UK
(IID2 study): incidence in the community and presenting to general
practice. Gut. 2012;61(1):69–77.
12. O'Brien SJ, et al. Methods for determining disease burden and calibrating
national surveillance data in the United Kingdom: the second study of
infectious intestinal disease in the community (IID2 study). BMC Med Res
Methodol. 2010;10:39.
13. Harris JP, Iturriza-Gomara M, O'Brien SJ. Re-assessing the total burden of
norovirus circulating in the United Kingdom population. Vaccine. 2017;35(6):
853–5.
14. de Wit MA, et al. Sensor, a population-based cohort study on gastroenteritis
in the Netherlands: incidence and etiology. Am J Epidemiol. 2001;154(7):
666–74.
15. O'Brien SJ, et al. Age-specific incidence rates for norovirus in the
community and presenting to primary healthcare facilities in the United
Kingdom. J Infect Dis. 2016;213(Suppl 1):S15–8.
16. Tam CC, et al. The second study of infectious intestinal disease (IID2):
increased rates of recurrent diarrhoea in individuals aged 65 years and
above. BMC Public Health. 2013;13:739.
17. Allen DJ, et al. Early detection of epidemic GII-4 norovirus strains in UK and
Malawi: role of surveillance of sporadic acute gastroenteritis in anticipating
global epidemics. PLoS One. 2016;11(4):e0146972.
18. Lopman BA, et al. Clinical manifestation of norovirus gastroenteritis in
health care settings. Clin Infect Dis. 2004;39(3):318–24.
19. Harris JP, et al. Deaths from norovirus among the elderly, England and
Wales. Emerg Infect Dis. 2008;14(10):1546–52.
20. Gallimore CI, et al. Multiple norovirus genotypes characterised from an
oyster-associated outbreak of gastroenteritis. Int J Food Microbiol. 2005;
103(3):323–30.
21. Zheng DP, et al. Norovirus classification and proposed strain nomenclature.
Virology. 2006;346(2):312–23.
22. R Core Team. R: A language and environment for statistical computing. Vienna:
R Foundation for Statistical Computing. 2018. https://www.R-project.org/.
23. Phillips G, et al. Diagnosing norovirus-associated infectious intestinal disease
using viral load. BMC Infect Dis. 2009;9(1):63.
24. Kroneman A, et al. Data quality of 5 years of central norovirus outbreak
reporting in the European Network for food-borne viruses. J Pub Health.
2008;30(1):82–90. https://doi.org/10.1093/pubmed/fdm080.
25. Public Health England National norovirus and rotavirus Report. Summary of
surveillance of norovirus and rotavirus https://assets.publishing.service.gov.
uk/government/uploads/system/uploads/attachment_data/file/695209/
Norovirus_update_2018_week_11.pdf.
26. Muenchhoff M, Goulder PJ. Sex differences in pediatric infectious diseases. J
Infect Dis. 2014;209(Suppl 3):S120–6.
27. Siebenga JJ, et al. High prevalence of prolonged norovirus shedding and
illness among hospitalized patients: a model for in vivo molecular evolution.
J Infect Dis. 2008;198(7):994–1001.
28. Sukhrie FH, et al. Chronic shedders as reservoir for nosocomial transmission
of norovirus. J Clin Microbiol. 2010;48(11):4303–5.
Harris et al. BMC Infectious Diseases           (2019) 19:87 Page 8 of 8
